Untreatable Eye Disease Improves With Avastin

Main Category: Eye Health / Blindness
Also Included In: Cancer / Oncology;  Radiology / Nuclear Medicine
Article Date: 24 Jun 2007 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

4.82 (11 votes)

Healthcare Prof:4 and a half stars

4.5 (2 votes)


Patients with radiation retinopathy who were destined to go blind within five years now can keep their sight longer through localized treatment with Avastin, a well-known cancer drug, according to a two-year study published in the June, 2007 Archives of Ophthalmology.

"This is a major breakthrough for eye cancer patients who are treated with radiation therapy and commonly develop radiation retinopathy," said Paul T. Finger, MD, lead author of the study and director of Ocular Tumor Services at the New York Eye and Ear Infirmary. "Avastin reduces abnormal blood vessel growth, stops leakage in the eye and the patients wind up seeing better. This is a first."

Until now, patients with inflammation or cancer of the eye's choroid, retina, orbit and paranasal sinuses were confronted with a catch-22 in terms of treatment. Radiation therapy is the treatment of choice for most patients; but, it commonly causes a troubling side effect -- radiation retinopathy.

Dr. Finger references in the study 6 patients who had plaque radiation therapy and developed radiation retinopathy, but he has now treated 28 patients successfully with Avastin, he says. "The drug improved or stabilized visual acuity in all cases by dramatically reducing blood vessel leakage and resultant swelling of the macula, the major causes of irreversible vision loss in radiation retinopathy," he said. He also noted that, "before these Avastin findings, there was no effective treatment for macular radiation retinopathy."

Avastin is a monoclonal anti-body which inhibits the formation of abnormal blood vessels by selectively blocking a substance known as vascular endothelial growth factor (VEGF). Avasitin (also called bevaciaumab) is used systemically (throughout the body) for some cancers and has been linked to the risk of stroke; but, in this new study, it was administered and stayed locally in the eye.

In February 2007, in a study published in The American Journal of Ophthalmology, Dr. Finger showed that treatment with Avastin had similar success in patients with radiation optic neuropathy.

The New York Eye and Ear Infirmary, the oldest specialty hospital in the Western Hemisphere, is the primary teaching hospital for the New York Medical College. It has approximately 142,000 outpatient visits annually and over 20,000 surgical procedures per year. It has one of the nation's most extensive eye, ear, nose and throat clinics.

Axel F. Bang PR & Marketing
66 Mathews Mill Rd.
Bedford Hills, NY 10507
United States
Axel F. Bang PR & Marketing

View drug information on Avastin.


Article adapted by Medical News Today from original press release.
Visit our eye health / blindness section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Mark Brown. "Untreatable Eye Disease Improves With Avastin." Medical News Today. MediLexicon, Intl., 24 Jun. 2007. Web.
9 Feb. 2012. <http://www.medicalnewstoday.com/releases/75071.php>

APA
Mark Brown. (2007, June 24). "Untreatable Eye Disease Improves With Avastin." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/75071.php.

Please note: If no author information is provided, the source is cited instead.


Eye Health / Blindness

Most Popular Articles



Follow Our Eye Health News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Eye Health / Blindness Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »